Rocaglates as dual-targeting agents for experimental cerebral malaria

Area of Science:

• Parasitology
• Pharmacology
• Immunology

Background:

• Cerebral malaria (CM) is a severe Plasmodium infection with high mortality and limited treatments.
• Artemisinin resistance in Plasmodium parasites further complicates malaria treatment options.

Purpose of the Study:

• To investigate the antiplasmodial and anti-inflammatory properties of the rocaglate CR-1-31B.
• To evaluate CR-1-31B as a potential therapeutic agent for cerebral malaria.

Main Methods:

• CR-1-31B's effect on Plasmodium falciparum eukaryotic initiation factor 4A (PfeIF4A) and RNA interaction was assessed.
• In vivo efficacy was tested in mouse models of Plasmodium berghei (CM) and Plasmodium chabaudi infection.
• Ex vivo replication of clinical Plasmodium falciparum isolates was evaluated.
• In vitro and in vivo inflammatory responses in myeloid cells were measured.

Main Results:

• CR-1-31B demonstrated potent prophylactic and therapeutic activity against Plasmodium parasites in vivo, including drug-resistant strains.
• A single dose of CR-1-31B protected mice against lethal CM.
• CR-1-31B inhibited Plasmodium falciparum replication in human erythrocytes ex vivo.
• The compound reduced pro-inflammatory responses in myeloid cells both in vitro and in vivo.

Conclusions:

• CR-1-31B exhibits significant antiplasmodial activity and effectively inhibits malaria-associated inflammation.
• Its dual action makes CR-1-31B a promising candidate for treating human cerebral malaria.